Merck’s ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults

 Merck’s ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults

Merck’s ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults

Shots:

  • ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection
  • ASPECT-NP resulted in affinity of ZERBAXA for treating HABP and VABP in patients, which will further help in filling sNDA to the US and EMA seeking its approval for HABP and VABP
  • ZERBAXA 1.5g (ceftolozane 1g and tazobactam 0.5g) is approved in the US for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis in adults

Click here to read full press release/ article | Ref: Merck | Image: MIT

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post